The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 23, 2018
Filed:
Aug. 15, 2008
Applicants:
Reza Dana, Newton, MA (US);
Mohammad Dastjerdi, Prairie Village, KS (US);
Inventors:
Reza Dana, Newton, MA (US);
Mohammad Dastjerdi, Prairie Village, KS (US);
Assignee:
The Schepens Eye Research Institute, Inc., Boston, MA (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 38/00 (2006.01); A61K 49/00 (2006.01); A61K 38/19 (2006.01); A61K 38/20 (2006.01); A61K 38/21 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 31/7105 (2006.01); A61K 38/06 (2006.01); A61K 38/13 (2006.01); A61K 38/18 (2006.01); A61K 45/06 (2006.01); A61K 36/82 (2006.01); A61K 36/87 (2006.01); A61K 36/16 (2006.01); A61K 36/258 (2006.01); A61K 36/45 (2006.01); A61K 36/537 (2006.01); A61K 31/7088 (2006.01); A61K 38/17 (2006.01);
U.S. Cl.
CPC ...
A61K 39/3955 (2013.01); A61K 9/0051 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 36/16 (2013.01); A61K 36/258 (2013.01); A61K 36/45 (2013.01); A61K 36/537 (2013.01); A61K 36/82 (2013.01); A61K 36/87 (2013.01); A61K 38/063 (2013.01); A61K 38/13 (2013.01); A61K 38/1709 (2013.01); A61K 38/1816 (2013.01); A61K 38/2006 (2013.01); A61K 38/21 (2013.01); A61K 45/06 (2013.01);
Abstract
The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.